Leuko is a startup spun out from MIT and the Madrid M+Vision Consortium and founded by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro. They are developing a platform technology, PointCheckTM, that combines optics and AI to make noninvasive blood testing easier, faster and more accessible than state-of-the art solutions. For its first application, Leuko aims to improve clinical outcomes for >2M cancer chemotherapy patients a year, reduce their chemotherapy-related hospital readmissions by 50% and save >$6B annually in healthcare cost.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/23/22 | $5,000,000 | Series A |
Good Growth Capital HTH IAG Capital Partners Nina Capital | undisclosed |
